Daraprim (Pyrimethamine) Patent Expiration, LOE Window & CMS Spending

Daraprim (Pyrimethamine) by Tilde Sciences: FDA Approved Brand (No Listed Patent), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $75,000 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTilde Sciences
FDA Application & PathwayN008578 (NDA)
Exclusivity / Cliff HorizonFDA Approved Brand (No Listed Patent)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($75,000 intro WAC)